4 results on '"Smaill, Fiona"'
Search Results
2. In HIV-1, immediate vs deferred antiretroviral therapy and isoniazid vs no isoniazid reduced severe illness at 30 mo.
- Author
-
Smaill, Fiona
- Subjects
- *
ANTIRETROVIRAL agents , *HIV seroconversion - Published
- 2015
- Full Text
- View/download PDF
3. Antivirals for Treatment of Influenza.
- Author
-
Hsu, Jonathan, Santesso, Nancy, Mustafa, Reem, Brozek, Jan, Yao Long Chen, Hopkins, Jessica P., Cheung, Adrienne, Hovhannisyan, Gayane, Ivanova, Liudmila, Flottorp, Signe A., Sæterdal, Ingvil, Wong, Arthur D., Tian, Jinhui, Uyeki, Timothy M., Akl, Elie A., Alonso-Coello, Pablo, Smaill, Fiona, and Schünemann, Holger J.
- Subjects
- *
RANDOMIZED controlled trials , *INFLUENZA , *ANTIVIRAL agents , *INFLUENZA treatment , *SCIENTIFIC observation , *DRUGS , *OSELTAMIVIR , *PATIENTS - Abstract
Background: Systematic reviews of randomized, controlled trials in patients with influenza suggest a lack of evidence about the effects of antiviral therapy on several patient-important outcomes of influenza. Purpose: To systematically review observational studies for benefits and harms of oseltamivir, zanamivir, amantadine, or rimantadine in the treatment of influenza. Data Sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, SIGLE, the Chinese Biomedical Literature Database, Panteleimon, and LILACS up to November 2010; contact with pharmaceutical companies; and reference lists. Study Selection: Observational studies in any language that compared single antiviral therapy with no therapy or other antiviral therapy, or that had no comparator, for influenza or influenza-like illness. Data Extraction: Two independent investigators extracted data. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach. Data Synthesis: 74 studies fulfilled the inclusion criteria. Metaanalyses of the few studies providing effects with adjustment for confounders suggest that, in high-risk populations, oral oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI, 0.13 to 0.43]; low-quality evidence), hospitalization (odds ratio, 0.75 [CI, 0.66 to 0.89]; low-quality evidence), and duration of symptoms (33 hours [CI, 21 to 45 hours]; very low-quality evidence) compared with no treatment. Earlier treatment with oseltamivir was generally associated with better outcomes. Inhaled zanamivir may lead to shorter symptom duration (23 hours [CI, 17 to 28 hours]; moderate-quality evidence) and fewer hospitalizations (odds ratio, 0.66 [CI, 0.37 to 1.18]) but more complications than no treatment. Direct comparison of oral oseltamivir and inhaled zanamivir suggests no important differences in key outcomes. Data from 1 study suggest that oral amantadine may reduce mortality and pneumonia associated with influenza A. No included study evaluated rimantadine. Limitations: Mortality was assessed in high-risk patients, and generalizability is limited. The overall body of evidence is limited by risk for confounding and selection, reporting, and publication bias. Conclusion: Therapy with oral oseltamivir and inhaled zanamivir may provide a net benefit over no treatment of influenza. However, as with the randomized trials, the confidence in the estimates of the effects for decision making is low to very low. Primary Funding Sources: World Health Organization and Mc- Master University. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.
- Author
-
Shafran, Stephen D., Mashinter, Laura D., Phillips, Peter, Lalonde, Richard G., Gill, John, Walsley, Sharon L., Toma, Emil, Conway, Brian, Fong, Ignatius W., Rachlis, Anita R., Williams, Kurt E., Garber, Gary E., Schlech III, Walter F., Smaill, Fiona, Gill, M John, Walmsley, Sharon L, Schlech, Walter F, and Pradier, C
- Subjects
- *
MYCOBACTERIAL disease treatment , *MYCOBACTERIUM avium - Abstract
Background: Highly active antiretroviral therapy (HAART) is associated with improvement or resolution of several HIV-associated opportunistic infections. Although prophylaxis against disseminated Mycobacterium avium complex infection may be successfully discontinued after a favorable response to HAART, the 1999 guidelines from the U.S. Public Health Service/Infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART.Objective: To examine the outcome among patients with disseminated M. avium complex infection whose antimycobacterial therapy was discontinued after a favorable response to HAART.Design: Retrospective chart review between May 2000 and May 2001.Setting: 13 Canadian HIV clinics.Patients: 52 HIV-infected adults (43 men; mean age, 37.3 years) in whom successful antimycobacterial therapy for disseminated M. avium complex infection was discontinued after a favorable virologic response to HAART.Measurements: Survival, survival free of disseminated M. avium complex infection, and CD4(+) cell count responses.Results: At the time of diagnosis of disseminated M. avium complex infection, the median CD4(+) cell count was 0.016 x 10(9) cells/L, and the median plasma HIV RNA level was 90 000 copies/mL (plasma HIV RNA levels were available for only 21 patients). The patients received a median of 32 months of antimycobacterial therapy that included ethambutol plus either clarithromycin or azithromycin. When antimycobacterial therapy was discontinued, the median CD4(+) cell count was 0.23 x 10(9) cells/L and the median plasma HIV RNA level was less than 50 copies/mL. A median of 20 months after discontinuation of antimycobacterial therapy, only 1 patient had developed recurrent M. avium complex disease (37 months after stopping antimycobacterial therapy). This patient had stopped HAART 2 months earlier because of uncontrolled HIV viremia. Twenty months after stopping antimycobacterial therapy, the other 51 patients had a median CD4(+) cell count of 0.288 x 10(9) cells/L; 34 (67%) had undetectable plasma HIV RNA levels, and 8 (15%) had plasma HIV RNA levels of 50 to 1000 copies/mL.Conclusions: Discontinuation of successful disseminated M. avium complex therapy after a successful response to HAART is safe and reduces patients' pill burdens, potential drug adverse effects, drug interactions, and costs of therapy. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.